ARWR vs CYTK
Arrowhead Pharmaceuticals, Inc. and Cytokinetics, Incorporated, both Healthcare
Arrowhead Pharmaceuticals, Inc. is the larger company at $11B against $11B. Over the past year ARWR returned +105% against +29% for CYTK. The RyuScore puts ARWR ahead, 18 against 11 out of 100.
| Figure | ARWR | CYTK |
|---|---|---|
| Last close | $62.78 | $62.93 |
| Market cap | $11B | $11B |
| 1-year return | +105% | +29% |
| 5-year return | +0.4% | +90% |
| RyuScoresector-relative, 1–10 | 18/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Arrowhead Pharmaceuticals, Inc.
Revenue of $75M in Q3 2026, net income null.
Cytokinetics, Incorporated
Revenue of $29M in Q2 2026, net income null. Its largest reported line is Net Product, 89% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.